About Justin Jordan, MD, MPH

Dr. Jordan earned his bachelor's degree in biology in 2004 from Texas Christian University, then his MD from the University of Texas Medical School in Houston. During that time he performed basic science and translational research on brain tumor immunology at the University of Texas M.D. Anderson Cancer Center in Houston.  He then completed his neurology residency at the University of Texas Southwestern Medical Center in Dallas, where he served as chief resident.  He trained in the neuro-oncology fellowship at the joint program of Massachusetts General Hospital, Dana Farber Cancer Institute, and Brigham and Women's Hospital.  In his second year of fellowship, he concentrated on the neurofibromatoses and allied disorders and enrolled in a Masters of Public Health degree program at the Harvard T.H. Chan School of Public Health, which he completed in November 2016.  He joined the clinical faculty of the Pappas Center for Neuro-Oncology and the Family Center for Neurofibromatosis in February 2015, and became Clinical Director of the MGH Brain Tumor Center in July 2017.

Dr. Jordan's clinical interests are in primary nervous system tumors and in neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.  His research interests are in the genetics of tumor development within these tumor predisposition syndromes, as well as therapeutic clinical trials for malignant brain tumors.  He is also involved in clinical process improvement for brain tumor care at MGH, and contributes to patient care quality measurement development within the American Academy of Neurology and the Society for Neuro-Oncology.

Departments, Centers, & Programs:

Clinical Interests:




Pappas Center for Neuro Oncology
55 Fruit Street
Boston, MA 02114
Phone: 617-724-8770

Mass General/North Shore Cancer Center
102 Endicott Street
Danvers, MA 01923-3623
Phone: 978-882-6060
Fax: 978-882-6070

Medical Education

  • MD, University of Texas Medical School-Houston
  • Residency, UT Southwestern Medical/Parkland
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Neurology, American Board of Psychiatry and Neurology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


  • View my most recent publications at PubMed

    • Jordan JT*, Sun W*, Hussain SF, Deangulo G, Prabhu SS, Heimberger AB. Preferential Migration of Regulatory T Cells Mediated by Glioma-Secreted Chemokines can be Blocked with Chemotherapy. Cancer Immunol Immunother. 2008 Jan; 57(1):123-31. * Denotes co-first authors
    • Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao W, Jordan JT, Stemmer-Rachamimov A, Plotkin SR, Gusella JF, Haggarty SJ, Ramesh V. “A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas” OncoTarget. 2015 July 15; 6(19):16981-16997.
    • Terry AR, Jordan JT, Schwamm L, Plotkin SR. “Increased risk of cerebrovascular disease among patients with neurofibromatosis type 1: A population-based approach” Stroke. 2016 Jan; 47(1):60-5.
    • Field KM*, Jordan JT*, Wen PY, Rosenthal MA, Reardon DA. Bevacizumab and Glioblastoma: Scientific Review, Newly Reported Updates, and Ongoing Controversies. April 1, 2015. * Denotes co-first authors
    • Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin, SR. Glioblastoma Care in the Elderly. Cancer. 2016 Jan 15;122(2):189-97.
    • Justin T. Jordan and Patrick Y. Wen. “Novel Chemotherapeutic Approaches in High-Grade Gliomas”, in Current Understanding and Treatment of Gliomas. Cancer Treatment and Research. Volume 163, 2015, pp117-142